NewsNovo
The case for MannKind Corporation's (Nasdaq: MNKD) $50 million private placement has a surface appeal: fresh institutional capital behind a company that just cleared an FDA milestone.
The complication is that $45 million of those proceeds are committed to a contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow, leaving limited proceeds for operations from the raise.
Placement structure The July 24, 2026 financing was led by Frazier Life Sciences, a longstanding biotech investment firm. MannKind is selling 10,440,838 shares of common stock at $3.89 per share.
Certain investors received pre-funded warrants in lieu of common stock, covering up to 2,412,632 shares at $3.88 per warrant with a $0.01 exercise price.
Keep reading